ClinicalTrials.gg
CompletedNCT03827798Updated Oct 16, 2026Results posted

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

A Phase 2 interventional study of CFZ533 and Placebo to CFZ533 in Hidradenitis Suppurativa, sponsored by Novartis Pharmaceuticals. Completed at 36 sites in 11 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Updated Oct 16, 2026Now CompletedPosted results revised+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
248
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Hidradenitis Suppurativa by Novartis — 9 open to participants now, 14 under way, 3 of them phase 3. Hidradenitis Suppurativa · Novartis.

Enrollment
7th of 10
248 · median 545
Started
2019
with 2 others
Phase 2
2 of 21
none open now
Registered
4th of 21
by date

Among the 21 studies in Hidradenitis Suppurativa by Novartis, this one is the 7th largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2019, is one of 2 in phase 2, and was the 4th registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

9 of the 21 studies in Hidradenitis Suppurativa by Novartis are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Hidradenitis Suppurativa by Novartis, or all of them as a file.
02

Study summary

The main purpose of this study is to assess preliminary efficacy and safety of CFZ533/iscalimab (Cohort A), LYS006 (Cohort B), MAS825 (Cohort C), LOU064/remibrutinib (Cohort D) and VAY736/ianalumab (Cohort E) in patients with moderate to severe hidradenitis suppurativa and to determine if CFZ533, LYS006, MAS825, LOU064 and VAY736 have an adequate clinical profile for further clinical development.

Read the detailed description

This is a randomized, subject and investigator-blinded, placebo-controlled, multi-center and parallel-group non-confirmatory study to assess the efficacy, safety and tolerability of five investigational drugs, CFZ533 (iscalimab), LYS006, MAS825, LOU064 (remibrutinib) and VAY736 (ianalumab) in subjects with moderate to severe hidradenitis suppurativa.

All participants from Cohorts A, B and C had planned a 16-week treatment period and 12-week safety follow up period. All participants for Cohort D had planned a 16-week treatment period and 4-week safety follow up period.

All participants for Cohort E had planned a 16-week treatment period and a mandatory 16-week safety follow-up period, plus a conditional follow-up period for up to 84 weeks for a total maximum follow up period of 2 years. Cohorts A-D are completed and Cohort E is ongoing.

03

Conditions studied

  • Hidradenitis Suppurativa

Keywords

  • Hidradenitis suppurativa
  • acne inversa
  • platform study
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with moderate to severe HS based on the number of lesions, fistulae and anatomical areas involved
  • Minimal body weight of 50 kg
  • Able to communicate well with the investigator and understand and comply with the requirements of the study, and the ability and willingness to conduct study visits as per the study schedule

Exclusion criteria

Exclusion Criteria:

  • Use of other drugs at the time of screening or before
  • Women physiologically capable of becoming pregnant, unless they are using highly effective methods of
  • Pregnant or lactating women

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
248 participants (actual)

Study arms

  • Experimental
    Cohort A - CFZ533 600 mg

    CFZ533 600 mg administered subcutaneous (s.c) weekly for 4 weeks, followed by bi-weekly until Week 15.

    Drug: CFZ533

  • Experimental
    Cohort B - LYS006 20 mg

    LYS006 20 mg administered orally twice per day until Week 16.

    Drug: LYS006

  • Placebo comparator
    Cohort A - Placebo to CFZ533

    Placebo administered subcutaneous (s.c) weekly for 4 weeks, followed by bi-weekly until Week 15.

    Drug: Placebo to CFZ533

  • Placebo comparator
    Cohort B - Placebo to LYS006

    Placebo administered orally twice per day until Week 16.

    Drug: Placebo to LYS006

  • Experimental
    Cohort C - MAS825 300 mg

    MAS825 300 mg administered s.c. bi-weekly for 4 weeks, followed by monthly until Week 13.

    Drug: MAS825

  • Placebo comparator
    Cohort C - Placebo to MAS825

    Placebo administered s.c. bi-weekly for 4 weeks, followed by monthly until Week 13.

    Drug: Placebo to MAS825

  • Experimental
    Cohort D - LOU064 25mg

    LOU064 25 mg administered orally twice per day until Week 16.

    Drug: LOU064 25mg

  • Experimental
    Cohort D - LOU064 100mg

    LOU064 100 mg administered orally twice per day until Week 16.

    Drug: LOU064 100mg

  • Placebo comparator
    Cohort D - Placebo to LOU064

    Placebo administered orally twice per day until Week 16.

    Drug: Placebo to LOU064

  • Experimental
    Cohort E - VAY736 300 mg

    VAY736 300 mg administered s.c every 4 weeks until Week 13.

    Drug: VAY736

  • Placebo comparator
    Cohort E - Placebo to VAY736

    Placebo administered s.c every 4 weeks until Week 13.

    Drug: Placebo to VAY736

Interventions

  • DrugCFZ533

    CFZ533 600 mg administered subcutaneous (s.c) weekly for 4 weeks, followed by bi-weekly until Week 15.

    Also known as: iscalimab

  • DrugPlacebo to CFZ533

    Placebo administered subcutaneous (s.c) weekly for 4 weeks, followed by bi-weekly until Week 15.

  • DrugLYS006

    LYS006 20 mg administered orally twice per day until Week 16.

  • DrugPlacebo to LYS006

    Placebo administered orally twice per day until Week 16.

  • DrugMAS825

    MAS825 300 mg administered s.c. bi-weekly for 4 weeks, followed by monthly until Week 13.

  • DrugPlacebo to MAS825

    Placebo administered s.c. bi-weekly for 4 weeks, followed by monthly until Week 13.

  • LOU064 25 mg administered orally twice per day until Week 16.

    Also known as: remibrutinib

  • LOU064 100 mg administered orally twice per day until Week 16.

    Also known as: remibrutinib

  • DrugPlacebo to LOU064

    Placebo administered orally twice per day until Week 16.

  • DrugVAY736

    VAY736 300 mg administered s.c every 4 weeks until Week 13.

    Also known as: ianalumab

  • DrugPlacebo to VAY736

    Placebo administered s.c every 4 weeks until Week 13.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Clinical Response Measured by Simplified Hidradenitis Suppurativa (sHiSCR)

    sHiSCR was defined as at least a 50 percent (%) reduction in abscess and inflammatory nodule (AN) counts, and no increase in draining fistula count related to baseline. The primary variable was modeled with the binomial distribution. A neutral non-informative Beta (1/3, 1/3) distribution was used as the prior for the response rate for all treatment groups. Based on the priors and the observed primary outcome, posterior distributions for the response rate for the investigational treatment and pooled placebo groups were computed respectively. At the time of the statistical comparison for cohorts A, B, and C, the placebo data for cohorts D and E were incomplete and therefore excluded. Similarly, during the comparison for cohort D, the placebo data for cohort E was still pending and was not included.

    Time frame: Baseline, Week 16

07

Results

Posted Feb 6, 2026

Participant flow

Participants took part in 36 investigative sites in 11 countries.

Treatment Epoch
Participant flow — Treatment Epoch
MilestoneCohort A - CFZ533 600 mgCohort A - Placebo to CFZ533Cohort B - LYS006 20 mgCohort B - Placebo to LYS006Cohort C - MAS825 300 mgCohort C - Placebo to MAS825Cohort D - LOU064 25 mgCohort D - LOU064 100 mgCohort D - Placebo to LOU064Cohort E - VAY736 300 mgCohort E - Placebo to VAY736
Started2916271333103333113211
Completed2512209299292682310
Not completed44744147391
Withdrew: Adverse event11111003000
Withdrew: Physician decision10121000000
Withdrew: Protocol deviation00100000000
Withdrew: Withdrawal by subject23412143281
Withdrew: Lost to follow-up00000001110
Entered post-treatment Follow-up
Participant flow — Entered post-treatment Follow-up
MilestoneCohort A - CFZ533 600 mgCohort A - Placebo to CFZ533Cohort B - LYS006 20 mgCohort B - Placebo to LYS006Cohort C - MAS825 300 mgCohort C - Placebo to MAS825Cohort D - LOU064 25 mgCohort D - LOU064 100 mgCohort D - Placebo to LOU064Cohort E - VAY736 300 mgCohort E - Placebo to VAY736
Started2612219289302782310
Completed24111982673025801
Not completed212122020239
Withdrew: Follow up ongoing000000000219
Withdrew: Lost to follow-up10112002000
Withdrew: Withdrawal by subject11100200020

Outcome measures

PrimaryPercentage of Participants Achieving Clinical Response Measured by Simplified Hidradenitis Suppurativa (sHiSCR)

sHiSCR was defined as at least a 50 percent (%) reduction in abscess and inflammatory nodule (AN) counts, and no increase in draining fistula count related to baseline. The primary variable was modeled with the binomial distribution. A neutral non-informative Beta (1/3, 1/3) distribution was used as the prior for the response rate for all treatment groups. Based on the priors and the observed primary outcome, posterior distributions for the response rate for the investigational treatment and pooled placebo groups were computed respectively. At the time of the statistical comparison for cohorts A, B, and C, the placebo data for cohorts D and E were incomplete and therefore excluded. Similarly, during the comparison for cohort D, the placebo data for cohort E was still pending and was not included.

Time frame:
Baseline, Week 16
Reported as:
Count of participants · Participants
Percentage of Participants Achieving Clinical Response Measured by Simplified Hidradenitis Suppurativa (sHiSCR)
ParticipantsCohort A - CFZ533 600 mgCohort B - LYS006 20 mgCohort C - MAS825 300 mgPooled Placebo (Cohorts A, B and C)Cohort D - LOU064 25 mgCohort D - LOU064 100 mgPooled Placebo (Cohorts A, B, C and D)Cohort E - VAY736 300 mgPooled Placebo (Cohorts A, B, C, D and E)
Percentage of Participants Achieving Clinical Response Measured by Simplified Hidradenitis Suppurativa (sHiSCR)17815142416171623
Statistical analysis
  • Cohort A - CFZ533 600 mg vs Pooled Placebo (Cohorts A, B and C) · Bayesian Analysis · Average difference in response rates: 22.1 · 90% CI 2.5 to 41.090% credible intervals of the treatment difference are reported as 90% Confidence Interval 2-Sided below.
  • Cohort A - CFZ533 600 mg vs Pooled Placebo (Cohorts A, B and C) · Bayesian Analysis · Probability (%) diff. in resp. rate >= 0: 97.1
  • Cohort B - LYS006 20 mg vs Pooled Placebo (Cohorts A, B and C) · Bayesian Analysis · Average difference in response rates: -3.3 · 90% CI -21.9 to 15.990% credible intervals of the treatment difference are reported as 90% Confidence Interval 2-Sided below.
  • Cohort B - LYS006 20 mg vs Pooled Placebo (Cohorts A, B and C) · Bayesian Analysis · Probability (%) diff. in resp. rate >= 0: 38.7
  • Cohort C - MAS825 300 mg vs Pooled Placebo (Cohorts A, B and C) · Bayesian Analysis · Average difference in response rates: 12.2 · 90% CI -7.5 to 31.690% credible intervals of the treatment difference are reported as 90% Confidence Interval 2-Sided below.
  • Cohort C - MAS825 300 mg vs Pooled Placebo (Cohorts A, B and C) · Bayesian Analysis · Probability (%) diff. in resp. rate >= 0: 84.7
  • Cohort D - LOU064 25 mg vs Pooled Placebo (Cohorts A, B, C and D) · Bayesian Analysis · Average difference in response rates: 37.2 · 90% CI 19.7 to 53.090% credible intervals of the treatment difference are reported as 90% Confidence Interval 2-Sided below.
  • Cohort D - LOU064 25 mg vs Pooled Placebo (Cohorts A, B, C and D) · Bayesian Analysis · Probability (%) diff. in resp. rate >= 0: 99.9
  • Cohort D - LOU064 100 mg vs Pooled Placebo (Cohorts A, B, C and D) · Bayesian Analysis · Average difference in response rates: 13.9 · 90% CI -4.2 to 31.990% credible intervals of the treatment difference are reported as 90% Confidence Interval 2-Sided below.
  • Cohort D - LOU064 100 mg vs Pooled Placebo (Cohorts A, B, C and D) · Bayesian Analysis · Probability (%) diff. in resp. rate >= 0: 89.6
  • Cohort E - VAY736 300 mg vs Pooled Placebo (Cohorts A, B, C, D and E) · Bayesian Analysis · Average difference in response rates: 13.4 · 90% CI -4.2 to 31.590% credible intervals of the treatment difference are reported as 90% Confidence Interval 2-Sided below.
  • Cohort E - VAY736 300 mg vs Pooled Placebo (Cohorts A, B, C, D and E) · Bayesian Analysis · Probability (%) diff. in resp. rate >= 0: 89.0

Adverse events

Collected over Cohorts A, B and C: 28 weeks including 12 weeks follow up period. Cohort D: 20 weeks including 4 weeks follow up period. Cohort E (ongoing): up to 116 weeks including 100 weeks follow up period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A - CFZ533 600 mg0/29 (0%)4/29 (13.8%)23/29 (79.3%)
Cohort B - LYS006 20 mg0/27 (0%)2/27 (7.4%)19/27 (70.4%)
Cohort C - MAS825 300 mg0/33 (0%)1/33 (3%)22/33 (66.7%)
Cohort D - LOU064 25 mg0/33 (0%)1/33 (3%)26/33 (78.8%)
Cohort D - LOU064 100 mg0/33 (0%)1/33 (3%)15/33 (45.5%)
Cohort E - VAY736 300 mg0/32 (0%)1/32 (3.1%)18/32 (56.3%)
Pooled Placebo (Cohorts A, B, C, D and E)0/61 (0%)1/61 (1.6%)38/61 (62.3%)
Total0/248 (0%)11/248 (4.4%)161/248 (64.9%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventCohort A - CFZ533 600 mgCohort B - LYS006 20 mgCohort C - MAS825 300 mgCohort D - LOU064 25 mgCohort D - LOU064 100 mgCohort E - VAY736 300 mgPooled Placebo (Cohorts A, B, C, D and E)Total
Blood creatine phosphokinase increasedInvestigations0/291/270/330/330/330/320/611/248
Alcohol withdrawal syndromePsychiatric disorders0/291/270/330/330/330/320/611/248
Abscess limbInfections and infestations1/290/270/330/330/330/320/611/248
Genital abscessInfections and infestations1/290/270/330/330/330/320/611/248
Ovarian cystReproductive system and breast disorders1/290/270/330/330/330/320/611/248
Testicular torsionReproductive system and breast disorders1/290/270/330/330/330/320/611/248
ColitisGastrointestinal disorders0/290/270/330/330/331/320/611/248
Pancreatitis acuteGastrointestinal disorders0/290/270/331/330/330/320/611/248
DepressionPsychiatric disorders0/290/271/330/330/330/320/611/248
Hypertensive crisisVascular disorders0/290/270/330/331/330/320/611/248
Most frequent other events
Showing 10 of 41
Most frequent other events
EventCohort A - CFZ533 600 mgCohort B - LYS006 20 mgCohort C - MAS825 300 mgCohort D - LOU064 25 mgCohort D - LOU064 100 mgCohort E - VAY736 300 mgPooled Placebo (Cohorts A, B, C, D and E)Total
COVID-19Infections and infestations3/291/278/332/332/330/323/6119/248
NasopharyngitisInfections and infestations1/294/273/337/332/334/323/6124/248
HidradenitisSkin and subcutaneous tissue disorders0/292/275/331/330/336/328/6122/248
Injection related reactionInjury, poisoning and procedural complications0/290/270/330/330/335/321/616/248
HeadacheNervous system disorders2/294/275/334/330/331/326/6122/248
FatigueGeneral disorders and administration site conditions1/294/273/333/331/330/324/6116/248
PyrexiaGeneral disorders and administration site conditions1/293/271/332/330/331/324/6112/248
Urine albumin/creatinine ratio increasedInvestigations2/293/271/331/331/330/322/6110/248
AstheniaGeneral disorders and administration site conditions3/290/272/332/330/330/324/6111/248
ArthralgiaMusculoskeletal and connective tissue disorders3/291/270/331/330/330/322/617/248

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort A - CFZ533 600 mgCohort A - Placebo to CFZ533Cohort B - LYS006 20 mgCohort B - Placebo to LYS006Cohort C - MAS825 300 mgCohort C - Placebo to MAS825Cohort D - LOU064 25 mgCohort D - LOU064 100 mgCohort D - Placebo to LOU064Cohort E - VAY736 300 mgCohort E - Placebo to VAY736Total
Mean38.0 ± 8.6841.4 ± 9.5436.4 ± 9.6236.5 ± 13.2939.5 ± 8.2236.9 ± 10.2635.6 ± 10.8435.3 ± 10.9944.1 ± 7.8334.6 ± 8.3533.1 ± 11.2637.0 ± 9.94
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A - CFZ533 600 mgCohort A - Placebo to CFZ533Cohort B - LYS006 20 mgCohort B - Placebo to LYS006Cohort C - MAS825 300 mgCohort C - Placebo to MAS825Cohort D - LOU064 25 mgCohort D - LOU064 100 mgCohort D - Placebo to LOU064Cohort E - VAY736 300 mgCohort E - Placebo to VAY736Total
Female161017719318203174134
Male13610614715138157114
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort A - CFZ533 600 mgCohort A - Placebo to CFZ533Cohort B - LYS006 20 mgCohort B - Placebo to LYS006Cohort C - MAS825 300 mgCohort C - Placebo to MAS825Cohort D - LOU064 25 mgCohort D - LOU064 100 mgCohort D - Placebo to LOU064Cohort E - VAY736 300 mgCohort E - Placebo to VAY736Total
Asian — Asian101000010104
Asian — Black Or African American1110101115113
Asian — Other101050200009
Asian — Unknown000010000001
Asian — White2615241326103031102610221
08

Study locations

36 sites
  • Olympian Clinical Research
    Clearwater, Florida 33609, United States
  • Park Avenue Dermatology PA
    Orange Park, Florida 32073, United States
  • University Of South Florida
    Tampa, Florida 33612, United States
  • Advanced Medical Research
    Sandy Springs, Georgia 30328, United States
  • NorthShore University Health System
    Evanston, Illinois 60201, United States
  • Dawes Fretzin Clinical Rea Group
    Indianapolis, Indiana 46256, United States
  • Penn State Milton S Hershey Medical Center
    Hershey, Pennsylvania 17033-0850, United States
  • Medical University of South Carolina MUSC
    Charleston, South Carolina 29425, United States
  • Novartis Investigative Site
    Graz, 8036, Austria
  • Novartis Investigative Site
    Brussels, 1070, Belgium
  • Novartis Investigative Site
    Prague, 110 00, Czechia
  • Novartis Investigative Site
    Copenhagen, 2400, Denmark
  • Novartis Investigative Site
    Roskilde, 4000, Denmark
  • Novartis Investigative Site
    Antony, 92160, France
  • Novartis Investigative Site
    Lyon, 69003, France
  • Novartis Investigative Site
    Marseille, 13885, France
  • Novartis Investigative Site
    Nice, 06202, France
  • Novartis Investigative Site
    Reims, 51100, France
  • Novartis Investigative Site
    Rouen, 76031, France
  • Novartis Investigative Site
    Frankfurt, Germany 60590, Germany
  • Novartis Investigative Site
    Bochum, 44791, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Schwerin, 19055, Germany
  • Novartis Investigative Site
    Pécs, Baranya 7623, Hungary
  • Novartis Investigative Site
    Debrecen, Hajdu Bihar Megye 4032, Hungary
  • Novartis Investigative Site
    Budapest, 1083, Hungary
  • Novartis Investigative Site
    Szeged, H 6725, Hungary
  • Novartis Investigative Site
    Kopavogur, 201, Iceland
  • Novartis Investigative Site
    Groningen, Provincie Groningen 9713 GZ, Netherlands
  • Novartis Investigative Site
    Rotterdam, South Holland 3015 GD, Netherlands
  • Novartis Investigative Site
    Granada, Andalusia 18014, Spain
  • Novartis Investigative Site
    Sabadell, Barcelona 08208, Spain
  • Novartis Investigative Site
    Manises, Valencia 46940, Spain
  • Novartis Investigative Site
    Barcelona, 08041, Spain
  • Novartis Investigative Site
    Las Palmas GC, 35010, Spain
  • Novartis Investigative Site
    Valencia, 46026, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Dec 2024, 69 months.

Results were first posted in Feb 2026, 1 year 2 months after primary completion.

Of 44 industry-sponsored phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 69 months is above that.

Counting every sponsor, half of 54 studies reached it within 15 months; a quarter within 11 and three quarters within 24.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Sep 2026, on Oct 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2019
First posted
Feb 1, 2019
StartActual
Feb 27, 2019
Primary completionActual
Dec 4, 2024
CompletionActual
Sep 11, 2026was Dec 2026
Results first posted
Feb 6, 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 16, 2026
Results
Posted results revised
revised Oct 16, 2026
Sites
3 sites added, 3 sites removed
Show 3 added (1 Czechia, 1 Germany, 1 Netherlands)
  • Novartis Investigative Site · Prague, Czechia
  • Novartis Investigative Site · Frankfurt, Germany
  • Novartis Investigative Site · Groningen, Netherlands
Show 3 removed
  • Novartis Investigative Site · Prague, Czechia
  • Novartis Investigative Site · Frankfurt, Germany
  • Novartis Investigative Site · Groningen, Netherlands
Oct 16, 2026
Study completion
Dec 11, 2026→Sep 11, 2026 (actual)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Active, not recruiting→Completed
    Posted results revised
    3 sites added, 3 sites removed
    Show 3 added (1 Czechia, 1 Germany, 1 Netherlands)
    • Novartis Investigative Site · Prague, Czechia
    • Novartis Investigative Site · Frankfurt, Germany
    • Novartis Investigative Site · Groningen, Netherlands
    Show 3 removed
    • Novartis Investigative Site · Prague, Czechia
    • Novartis Investigative Site · Frankfurt, Germany
    • Novartis Investigative Site · Groningen, Netherlands
    Study completion Dec 11, 2026→Sep 11, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03827798
Responsible party
Sponsor
First posted
Feb 1, 2019
Start date
Feb 27, 2019
Primary completion
Dec 4, 2024
Completion
Sep 11, 2026
Results posted
Feb 6, 2026
Last update
Oct 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Iscalimab · LYS-006 · Arumakimig · Remibrutinib · Ianalumab

Start the discussion